Cocrystal Pharma, Inc.
COCP
Rank in Stocks
#26255
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching... Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.
Share Price
$1.11
Last synced: 2026-11-09
Market Cap
$21.29M
Change (1 day)
6.25%
Change (1 year)
-2.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cocrystal Pharma, Inc. (COCP)
Category
Healthcare
EPS for Cocrystal Pharma, Inc. (COCP)
EPS as of June 2026 TTM: $-0.80
According to Cocrystal Pharma, Inc.'s latest financial reports, its current EPS (TTM) is $-0.80. At the end of 2025 the company had an EPS of $-0.78, an increase over its 2024 EPS of $-1.72.
EPS history for Cocrystal Pharma, Inc. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.80 | 2.56% |
| 2025 | $-0.78 | -54.65% |
| 2024 | $-1.72 | 90,426.32% |
| 2023 | 0.00 | -99.96% |
| 2022 | $-4.77 | 157.84% |
| 2021 | $-1.85 | -7.96% |
| 2020 | $-2.01 | -87.26% |
| 2019 | $-15.78 | -24.89% |
| 2018 | $-21.01 | 6,903.33% |
| 2017 | $-0.30 | -99.21% |
| 2016 | $-38.17 | 33.46% |
| 2015 | $-28.60 | 9,762.07% |
| 2014 | $-0.29 | -99.53% |
| 2013 | $-62.00 | 36.53% |
| 2012 | $-45.41 | 27.56% |
| 2011 | $-35.60 | 9,028.21% |
| 2010 | $-0.39 | -2.50% |
| 2009 | $-0.40 | -21.57% |
| 2008 | $-0.51 | -17.74% |
| 2007 | $-0.62 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,057.50% |
US
|
|
| $-7.07 | 783.75% |
US
|
|
| $-5.29 | 561.25% |
AU
|
|
| $12.88 | -1,710.01% |
BE
|
|
| $21.56 | -2,795.00% |
NL
|
Questions about Cocrystal Pharma, Inc.'s earnings per share (EPS)
What is Cocrystal Pharma, Inc.'s earnings per share (EPS)?
Cocrystal Pharma, Inc.'s earnings per share (EPS) over the last twelve months is $-0.80, as of Jun 2026.
What was Cocrystal Pharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Cocrystal Pharma, Inc.'s earnings per share (EPS) was $-0.78, compared with $-1.72 in 2024.
How has Cocrystal Pharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cocrystal Pharma, Inc.'s earnings per share (EPS) was highest in 2023 (0.00) and lowest in 2022 ($-4.77).
How does Cocrystal Pharma, Inc.'s earnings per share (EPS) compare with similar companies?
Cocrystal Pharma, Inc.'s earnings per share (EPS) ($-0.80) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.